Abstract
Background: Atherosclerosis is considered to be a chronic inflammatory disorder. Several large‐scale clinical studies demonstrate that markers of inflammation, such as high‐sensitivity C‐reactive protein (hsCRP), fibrinogen, and soluble CD40 ligand, are potent and independent predictors of vascular risk.
Hypothesis: The study was undertaken to investigate the effect of increasing the statin dose from conventional to aggressive treatment on lipids levels, inflammation, and endothelial function in patients with coronary artery disease (CAD).
Methods: We randomized 97 patients to either 20 mg simvastatin or 80 mg atorvastatin. Plasma levels of lipids, hsCRP, fibrinogen, soluble adhesion molecules, and nitric oxide‐total were analyzed at baseline and after 6 months of treatment.
Results: Lipid values were significantly reduced in both treatment groups, but with significantly greater reduction in the aggressively treated group. Furthermore, aggressive statin treatment significantly decreased hsCRP and fibrinogen, while only small reductions were seen in the conventionally treated group, resulting in significant differences between the two treatment groups (p < 0.001). Nitric oxide‐total increased significantly in both treatment groups, although the increase was more pronounced in the aggressively treated group (22.6 vs. 15.6%).
Conclusion: Aggressive statin treatment significantly improved lipid status and reduced markers of inflammation and improved endothelial function compared with conventional treatment in patients with CAD. No interaction was observed, and high‐dose treatment did not offer additional benefit compared with standard‐dose treatment with respect to soluble adhesion molecules.
Keywords: statin treatment, inflammation, endothelial markers
Full Text
The Full Text of this article is available as a PDF (38.2 KB).
References
- 1. Ross R: Atherosclerosis‐an inflammatory disease. N Engl J Med 1999; 340: 115–126 [DOI] [PubMed] [Google Scholar]
- 2. Ridker PM: Are statins anti‐inflammatory? Issues in the design and conduct of the pravastatin inflammation C‐reactive protein evaluation. Curr Cardiol Rep 2000; 2: 269–273 [DOI] [PubMed] [Google Scholar]
- 3. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–1082 [DOI] [PubMed] [Google Scholar]
- 4. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium‐dependent vasodilatation in hyper‐cholesterolemic humans. Circulation 1997; 95: 76–82 [DOI] [PubMed] [Google Scholar]
- 5. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease : The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
- 6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
- 7. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG‐coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–1131 [DOI] [PubMed] [Google Scholar]
- 8. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334–1338 [DOI] [PubMed] [Google Scholar]
- 9. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS: Effect of folic acid treatment on endothelium‐dependent vasodilation and nitric oxide‐derived end products in hyperhomocysteinemic subjects. Am J Med 2001; 110: 536–542 [DOI] [PubMed] [Google Scholar]
- 10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C‐reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425–428 [DOI] [PubMed] [Google Scholar]
- 11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–1565 [DOI] [PubMed] [Google Scholar]
- 12. Rosenson RS: Non‐lipid‐lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225–232 [DOI] [PubMed] [Google Scholar]
- 13. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hyper‐cholesterolemia. J Am Coll Cardiol 2000; 36: 427–431 [DOI] [PubMed] [Google Scholar]
- 14. Delanty N, Vaughan CJ: Vascular effects of statins in stroke. Stroke 1997; 28: 2315–2320 [DOI] [PubMed] [Google Scholar]
- 15. Azar RR, Waters DD: PRINCE's prospects: Statins, inflammation, and coronary risk. Am Heart J 2001; 141: 881–883 [DOI] [PubMed] [Google Scholar]
- 16. Wiklund O, Mattsson‐Hulten L, Hurt‐Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002; 251: 338–347 [DOI] [PubMed] [Google Scholar]
- 17. Jialal I, Stein D, Balis D, Grundy SM, Adams‐Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme, a reductase inhibitor therapy on high sensitive C‐reactive protein levels. Circulation 2001; 103: 1933–1935 [DOI] [PubMed] [Google Scholar]
- 18. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85: 47–51 [PubMed] [Google Scholar]
- 19. Ridker PM: High‐sensitivity C‐reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–1818 [DOI] [PubMed] [Google Scholar]
- 20. Ridker PM, Glynn RJ, Hennekens CH: C‐reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–2011 [DOI] [PubMed] [Google Scholar]
- 21. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB: C‐reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733–1740 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE: C‐reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999; 100: 96–102 [DOI] [PubMed] [Google Scholar]
- 23. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE: C‐reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97–103 [DOI] [PubMed] [Google Scholar]
- 24. Ma J, Hennekens CH, Ridker PM, Stampfer MJ: A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999; 33: 1347–1352 [DOI] [PubMed] [Google Scholar]
- 25. Resch KL, Ernst E, Matrai A, Paulsen HF: Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117: 371–375 [DOI] [PubMed] [Google Scholar]
- 26. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641 [DOI] [PubMed] [Google Scholar]
- 27. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225–233 [DOI] [PubMed] [Google Scholar]
- 28. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A: Effect of three fibrate derivatives and of two HMG‐CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241–243 [PubMed] [Google Scholar]
- 29. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA: Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 569–570 [DOI] [PubMed] [Google Scholar]
- 30. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J: Atorvastatin: An effective lipid‐modifying agent in familial hypercholester‐olemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527–1531 [DOI] [PubMed] [Google Scholar]
- 31. Davidson M, McKenney J, Stein E, Schrott H, Bakker‐Arkema R, Fayyad R, Black D: Comparison of one‐year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475–1481 [DOI] [PubMed] [Google Scholar]
- 32. Dimmeler S, Aicher A, Vasa M, Mildner‐Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG‐CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3‐kinase/Akt pathway. J Clin Invest 2001; 108: 391–397 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Hernandez‐Perera O, Perez‐Sala D, Navarro‐Antolin J, Sanchez‐Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3‐hydroxy‐3‐methylglu‐taryl‐CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin‐1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711–2719 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. John R, Rajasinghe HA, Itescu S, Suratwalla S, Lietz K, Weinberg AD, Kocher A, Mancini DM, Drusin RE, Oz MC, Smith CR, Rose EA, Edwards NM: Factors affecting long‐term survival (>10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 2001; 37: 189–194 [DOI] [PubMed] [Google Scholar]
- 35. Laufs U, Endres M, Liao JK: Regulation of endothelial NO production by Rho GTPase. Med Klin 1999; 94: 211–218 [DOI] [PubMed] [Google Scholar]